Patient & Clinical Trial FAQ

Looking for information about REOLYSIN® clinical trials? Find answers to some of the most commonly asked questions about participating in clinical trials and accessing REOLYSIN® below.

If you are interested in receiving information about availability of, or participation in, a clinical trial using REOLYSIN®, please read the following:

Oncolytics Biotech Inc. does not have any influence over the decision to enrol a patient in a clinical trial using REOLYSIN®, nor do its individual officers, directors or employees. Should a patient wish to be considered for enrolment in any clinical trial, his or her treating physician must contact a trial site directly using the contact information provided in the links below. The trial site will evaluate whether the patient meets the criteria for enrolment and render an independent decision about his or her inclusion in the trial on this basis.

If you are interested in receiving information about accessing REOLYSIN® outside of a clinical trial setting, please read the following:

REOLYSIN® is currently available only in a clinical trial setting, and has not received regulatory approval for sale in any jurisdiction.

Oncolytics Biotech Inc. does not currently have a formal Expanded Access program in the United States, nor an equivalent program in any other jurisdiction. We regret that we are unable to advise patients regarding the mechanisms that may or may not be available for compassionate or special access to REOLYSIN® and/or any other therapies in their countries of residence.

The following is a complete list of all clinical trials of REOLYSIN® which are currently open to patient enrolment, including the contact information and the inclusion and exclusion criteria for patient participation. (Please note that all links below are to third party sites.)

  • MC-1472, a U.S. based study of REOLYSIN® in combination with GM-CSF for pediatric patients with relapsed or refractory brain tumors.
  • NCI-9603, a U.S. based study of REOLYSIN® in combination with dexamethasone and carfilzomib (KYPROLIS®) for patients with relapsed or refractory multiple myeloma.
  • REO 019, a U.S. based study of REOLYSIN® in combination with bortezomib (VELCADE®) and dexamethasone for patients with relapsed or refractory multiple myeloma.
  • REO 024, a U.S. based study of REOLYSIN® in combination with pembrolizumab (KEYTRUDA®) and chemotherapy for patients with advanced or metastatic pancreatic adenocarcinoma.

Oncolytics does, from time to time, announce new clinical studies using REOLYSIN®. Patients are welcome to subscribe to our email updates in order to receive notifications of these and other developments with the Company.

If you are interested in receiving information about whether REOLYSIN® may be a suitable treatment option for a particular patient, please reading the following:

While Oncolytics Biotech Inc. is pleased to answer general questions about REOLYSIN®, we regret that we are unable to review prospective patients’ medical records and/or to provide medical advice or a treatment plan for any individual patient. Any patient who is interested in the possibility of participating in a clinical trial using REOLYSIN®, or who wishes to seek special or compassionate access to REOLYSIN®, should first discuss these (and all other) treatment options with his or her treating physician(s).

If we have not answered your question in these FAQ, you can contact our clinical team at clinical@oncolyticsbiotech.com, and we will respond to you as soon as possible.